Author:
Lopez Dolores Remedios Serrano,Lalatsa Aikaterini
Reference183 articles.
1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumour penetration of single-chain fv antibody molecules. Cancer Res 61(12):4750–4755
2. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16(6):1503–1511
3. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–515
4. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763
5. Allen D, Smith Q (2001) Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem 76(4):1032–1041